Systemic and global toxicities of head and neck treatment

Expert Review of Anticancer Therapy

Volumn 7, Issue 7, 2007, Pages 1043-1053

  Murphy, Barbara A ^a   Gilbert, Jill ^a   Ridner, Sheila H ^b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF NURSING   (United States)

Author keywords

Cytokines; Deconditioning; Fatigue; Head and neck cancer; Mucositis; Toxicity; Weight loss

Indexed keywords

ANTINEOPLASTIC AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 6; OPIATE; PACLITAXEL; TUMOR NECROSIS FACTOR ALPHA;

AGE; ANXIETY DISORDER; ARTHRALGIA; BODY WEIGHT DISORDER; BREAST CANCER; CANCER PAIN; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COPING BEHAVIOR; CYTOKINE PRODUCTION; DAILY LIFE ACTIVITY; DEPRESSION; DIET THERAPY; DISTRESS SYNDROME; DNA DAMAGE; DYSPHAGIA; ETHNICITY; FATIGUE; FLU LIKE SYNDROME; GENETIC PREDISPOSITION; HEAD AND NECK CANCER; HUMAN; LARYNX CANCER; LYMPHADENECTOMY; LYMPHEDEMA; MOOD DISORDER; MUCOSA INFLAMMATION; NONHUMAN; NUTRITIONAL DEFICIENCY; OROPHARYNX CANCER; PAIN; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; PHYSICAL DISABILITY; PSYCHOLOGICAL WELL BEING; RADIATION INJURY; REVIEW; RISK FACTOR; SEX DIFFERENCE; SPEECH DISORDER; SQUAMOUS CELL CARCINOMA; WEIGHT REDUCTION;

DRUG TOXICITY; FATIGUE; HEAD AND NECK NEOPLASMS; HUMANS; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATIONS; QUALITY OF LIFE; RADIATION INJURIES; SURVIVAL RATE; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 34547539155     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.7.7.1043     Document Type: Review

References (68)

1. Wilson IB, Cleary PD. Health-related quality of life, a conceptual model of patient outcomes. JAMA 273, 59-63 (1995).
2. Hickok JT, Morrow GR, Roscoe JA, Mustian K, Okunieff P. Occurrence, severity, and longitudinal course of twelve common symptoms in 1129 consecutive patients during radiotherapy for cancer. J. Pain Symptom. Manage. 30, 433-442 (2005).
3. Maccormick RE. Possible acceleration of aging by adjuvant chemotherapy: a cause of early onset frailty? Med. Hypotheses 67, 212-215 (2006).
4. Danzer R, Bluthc RM, Kent S, Goodall G. Behavioral effects of cytokines: an insight into mechanisms of sickness behavior. J. Neurosci. Methods 17, 130-150 (1993).
5. Pusztai L, Mendoza TR, Reuben JM et al. Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cyrokine 25, 94-102 (2004).
6. Bower JE, Ganz PA, Aziz N, Fahey JL. Fatigue and proinflammatory cytokine activity in breast cancer survivors. Psychosom. Med. 64, 604-611 (2002).
7. Chansky K, Benedetti J, Macdonald JS. Differences in toxicity between men and women treated with 5-fluorouracil therapy for colorectal carcinoma. Cancer 103, 1165-1171 (2005).
8. McCollum AD, Catalano PJ, Haller DG et al. Outcomes and toxicity in African American and Caucasian patients in a randomized adjuvnat trial for colon cancer. J. Natl Cancer Inst. 39, 91-100 (2002).
9. Vera-Llonch M, Oster G, Hagiwara M et al. Oral mucositis in patients undergoing radiation treatment for head and neck carcinoma. Cancer 06, 329-336 (2006).
10. Barasch A, Peterson DE. Risk factors for ulcerative oral mucositis in cancer patients: unanswered questions. Oral Oncol. 39, 91-100 (2003).
11. Bjarnason GA, Mackenzie R, Hodson I et al. A randomized prospective Phasc-III study comparing the acute oral mucositis of morning vs. afternoon radiotherapy (RT) in patients (pts) with squamous cell carcinoma of the head and neck (SCCHN): NCIC-CTG HN.3. Proc. Am. Soc. Clin. Oncol. 23, 500 (2005) (Abstract 5500).
12. Anthony L, Bowen J, Garden A, Hewson I, Sonis S. New thoughts on the pathobiology of regimen-related mucosal injury. Support. Care Cancer 14, 516-518 (2006).
13. Worthington HV Clarkson JE, Eden OB. Interventions for preventing oral mucosicis for patients with cancer receiving treatment. Cochrane Database Syst. Rev. 2, CDO00978 (2007).
14. Trotti A, Bellm LA, Epstein JB et al. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother. Oncol 66, 253-262 (2003).
15. Sonis ST. The pathobiology of mucositis. Nat. Rev. Cancer 4, 277-284 (2004).
16. Sonis ST, Elting LS, Keefe D. Perspectives on cancer therapy-induced mucosal injury pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 100(Suppl.), 1995-2025 (2004).
17. Blijlevens N, Sonis S. Palifermin (recombinant keratinocyte growth factor-1): a pleiotropic growth factor with multiple biological activities in preventing chemotherapy- and radio therapy-induced mucositis. Ann. Oncol. 18(5), 817-826 (2007).
18. Logan RM, Gobson RJ, Sonis S, Keefe D. Nuclear factor-κB (NF-κB) and cyclooxygenase-2 (COX-2) expression in the oral mucosa following cancer chemotherapy. Oral Oncol. 43(4), 395-401 (2006).
19. Trotti A. Toxicity in head and neck cancer: a review of trends and issues. Int. J Radiat. Oncol. Biol. Phys. 47, 1-12 (2000).
20. Duncan GG, Epstein JB, Tu D et al. Quality of life, mucositis, and xerostomia from radiotherapy for head and neck cancers: a report from the NCIC CTG HN2 randomized trial of an antimicrobial lozenge to prevent mucositis. Head Neck 27, 421-428 (2005).
21. Wong PC, Dodd, MJ, Miaskowski C et al. Mucositis pain induced by radiation therapy: prevalence, severity, and use of self-care behaviors. J. Pain Symptom Manage. 32, 27-37(2006).
22. Isitt J, Murphy BA, Beaumont JL et al. Oral mucositis (OM) related morbidity and resource utilization is a prospective study of head and neck cancer (HNQ patients. Proc. Am. Soc. Clin. Oncol. 24, 289 (2006) (Abstract 5539).
23. Chan KS, Reddy SK, Lee MC, Part RB. Pain and toss of function in head and neck cancer survivors. J Pain Symptom Manage. 18, 193-202 (1999).
24. Murphy BA, Cmelak A, Bayles S, Dowling E, Billante C. Head and neck cancer. In: Oxford Textbook of Palliative Medicine. Oxford University Press, Oxford, UK 658-672 (2004).
25. Dewys WD, B egg C, Lavin PT et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Am. J. Medicine 69, 491-497 (1980).
26. Brookes GB. Nutritional status - a prognostic indicator in head and neck cancer. Otolaryngol Head Neck Surg. 93, 69-74 (1985).
27. Lees J. Incidence ofweight loss in head and neck cancer patients on combined radiotherapy treatment at a regional oncology centre. Int. J Radiat. Oncol. Biol. Phys. 36, 1205-120) (1999).
28. Lin A, Jabbari S, Worden FP et al. Metabolic abnormalities associated with weight loss during chemoirradiation of head and neck cancer. Int. J Radiation Biol. Phys. 63, 1413-1418 (2005).
29. Lee JH, Machtay M, Unger LD et al. Prophylactic gastrostomy tubes in patients undergoing intensive irradiation for cancer of the head and neck. Arch. Otolaryngol. Head Neck Surg. 124(8),871-875 (1998).
30. Tytdestey S, Sheehan F, Munk P et al. The use of radiotogically placed gastrostomy tubes in head and neck cancer patients receiving radiotherapy. Int. J. Radiat. Oncol. Biol Phys. 36, 1205-1209 (1996).
31. Gianotti L, Braga M, Radaetli G, Mariani L, Vignali A, Di Carlo V. Lack of improvement of prognostic performance of weight loss when combined with other parameters. Nutrition 105, 62-73 (1995).
32. Murphy BA, Friedmann J, Dowling E, Cheatham R, Cmelak A. Dietary intake and adapations in head and neck cancer patients treated with chemoradiation. Proc. Am. Soc. Clin. Oncol. 21 (2002) (Abstract 932).
33. Silver HJ, Wellman NS, Arnold DJ, Livingstone AS, Byers PM. Older adults on home enteral nutrition: enteral regimen, provider involvement, and health care outcomes. JPEN J. Parenter. Enteral. Nutr. 28(2), 92-98 (2004).
34. Murphy BA, Lewin J, Ridncr S, Trotti A. Mechanism ofweight loss in head and neck cancer patients treated with chemoradiation. In: American Society of Clinical Oncolgoy 2006 Educational Book. American Society of Clinical Oncology, VA, USA 340-344 (2006).
35. Silver HJ, Dietrich MS, Murphy BA. Loss of lean body mass and associated physical function decline in the context ofincreased energy expenditure and inflammatory state in head and neck cancer patients undergoing concurrent chemo-radiation therapy. Head Neck (2007) (In press).
36. Rosenthal DL Lewin J, Eisbruch A. Prevention and treatment of dysphagia and aspiration after chemoradiation for head and neck cancer. J. Clin. Oncol. 24, 2636-2643 (2006).
37. Murphy BA, Smith K, Dowling E, Cmelak A, Burkey B, Forastiere A. Swallowing function for patients treated on E2399, a Phase II trial of function preservation with induction paclitaxel/carboplatin followed by radiation plus weekly paclitaxet. Proc. Am. Soc. Clin. Oncol. 24, 286 (2006) (Abstract 5524).
38. van Wilgen CP, Dijstra PU, van der Laan BF, Plukker JTM, Roodenburg JL. Morbidity of the neck after head and neck cancer therapy. Head Neck 26, 785-791 (2004).
39. Cappiello J, Piazza C, Giudice M. De Maria G, Nicolai P. Shoulder disability after different selective neck dissections (level II-IV versus levels II-V): a comparative study. Laryngoscope 115, 259-263 (2005).
40. Silver HJ, Horn PS, Murphy BA. Relationship between body composition changes, inflammation and physical functionality in head and neck cancer patients undergoing concurrent chemoradiation. FASEB J. 20, A143 (2006).
41. Mitchell SA, Berger AM. Cancer-related fatigue: the evidence base for assessment and management. Cancer J. 12, 374-387 (2006).
42. Conn VS, Hafidahl AR, Porock DC, McDaniel R, Nielsen PJ. A meta-analysis of exercise interventions among people treated for cancer. Support. Care Cancer 14, 699-712 (2006).
43. Dantzer R, Kelley KW. Twenty years of research in cytokine-induced sickness behavior. Brain Behav. Immun. 21(2), 153-160 (2007).
44. Dantzer R, Kelley KW. Stress and immunity: an integrated view of the relationship between the brain and the immune system. Life Sci. 44, 1995-2008 (1989).
45. Taylor JC, Terrell JE, Ronis DL et al. Disability in patients with head and neck cancer. Arch. Otolaryngol. 130, 764-769 (2004).
46. Disease ofthe Lymphatics. Browse N, Burnand KG, Mortimer PS (Eds). Arnold, London, UK (2003).
47. Foldi M, Foldi E, Kubik S. Textbook of Lymphology for Physicians and Lymphedema Therapists. Urban & Fischer, Munchen, Germany (2003).
48. Harris GJ, Woo KI, Schultz CJ et al. Late-onset chemosis in patients with head or neck tumors. Ophthal. Plait. Reconstr Surg. 20, 436-441 (2004).
49. Micke O, Bruns F, Mucke R et al. Selenium in the treatment of radiation-associated secondary lymphedema. Int. J. Radiation Oncology Biol. Phys. 56, 40-49 (2003).
50. Fajardo LF. Effects of ionizing radiation on lymph nodes. Front. Radiat. Ther. Oncol. 28, 37-45 (1994).
51. Guyton AC, Hall JE. Textbook of Medical Physiology (10th Edition). Saunders, PA, USA (2000).
52. Ridner SH. Breast cancer lymphedema: pathophysiotogy and risk reduction guidelines. Oncol. Nurs. Forum 29, 1285-1293 (2002).
53. Tabibiazar R, Cheung L, Han J et al. Inflammatory manifestations of experimental lymphatic insufficiency. PLoS Med. 3, 1114-1139 (2006).
54. Zeller JL. High suicide risk for patients with head and neck cancer. JAMA 296, 1716-1717 (2006).
55. Kendel W. Suicide and cancer: a gender-comparative study. Ann. Oncol. 18, 381-387 (2007).
56. Zabora J, Brintzenhofeszoc K, Curbow B, Hooker C, Piantadosi S. The prevalence of psychological distress by cancer site. Psycho-oncology 10, 19-28 (2001).
57. Haman K, Murphy B, Compas B. Social anxiety in head and neck cancer patients. Presented at: American Psychological Oncology Society Annual Meeting. Phoenix, AZ, USA, 27-29 January 2005.
58. Haman K, Smith B, Murphy B, Compas B. Predictors of quality of life in head and neck cancer patients. Presented at: American Psychological Oncological Society Annual Meeting. Amelia Island, FL, USA, 16-19 February (2006).
59. Sullivan MD, Edtund MJ, Zhang L et al. Association between mental health disorders, problem drug use and regular prescription opioid use. Arch. Intern. Med. 166, 2087-2093 (2006).
60. Reiger DA, Farmer ME, Rae DS et al. Comorbidity of mental disorders with alcohol and other drug abuse. JAMA 264, 2511-2518 (1990).
61. Harris DS, Wolkowitz OM, Reus VI. Psychoneumendocrinology In: Kaplan and Sadock's Comprehensive Textbook of Psychiatry (8th Edition). Lippincott Williams & Wilkins, MD, USA 126-137 (2005).
62. Raison CL, Capupron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 27, 24-31 (2006).
63. Schiepers OJG, Wichers MC, Maes M. Cytokines and major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 29, 201-217 (2005).
64. Kenis G, Maes M. Effects of antidepressants on the production of cytokines. Int. J. Neuropsychopharmacol. 5,401-412 (2002).
65. Leonard BE. The immune system, depression and the action of antidepressants. Prog. Neuropychopharmacol Biol Psychiatry 25, 767-780 (2001).
66. Pitsavos C, Panagiotakos DB, Papageorgiou C et al. Anxiety in relation to inflammation and coagulation markets, among healthy adults: the ATTICA Study. Atherosclerosis 185, 320-326 (2006).
67. Melmamed S, Shirom A, Toker S et al. Association of fear of terror with low-grade inflammation among apparently healthy employed adults. Psychosom. Med. 66, 484-491 (2004).
68. Rapaport MH, Stein MB. Serum cytokine and soluble interleukin-2 receptors in patients with panic disorder. Anxiety 1, 22-25 (1999).